Treatment of atopic dermatitis

Tae Young Han, Chan Ho Na, Ji Hyun Lee, Hye One Kim, Chang Ook Park, Young Joon Seo, Sang Wook Son, Min Kyung Shin, Ji Young Ahn, Yang Won Lee, Yong Hyun Jang, Young Lip Park, Bark Lynn Lew

Research output: Contribution to journalReview articlepeer-review


Atopic dermatitis (AD) is a common, chronic, relapsing, inflammatory skin disease that affects both children and adults. AD is the cause of considerable morbidity including severe pruritus and impaired quality of life. Treatments for active disease include avoidance of triggering factors, barrier repair, topical medications including topical corticosteroids (TCs) and topical calcineurin inhibitors (TCIs), phototherapy, antibacterial agents, and systemic immunosuppressants including cyclosporine. Until recently, the only Food and Drug Administration (FDA)-approved systemic treatment options for patients with moderate-to-severe AD were steroids and cyclosporine. Systemic steroids are not recommended by current guidelines and are commonly associated with disease rebound. Instead, clinicians choose from several off-label immunosuppressants. In 2018, the Korean FDA approved dupilumab for adults with moderate-to-severe AD whose disease is not adequately controlled with topical therapies. The implementation of treatment guidelines for AD is challenging. Herein, we review the several treatment modalities for AD and recommend a treatment algorithm.

Original languageEnglish
Pages (from-to)581-593
Number of pages13
JournalKorean Journal of Dermatology
Issue number10
Publication statusPublished - 2018 Dec

Bibliographical note

Publisher Copyright:
© 2018 GSK group of companies or its licensor.


  • Atopic dermatitis
  • Guideline
  • Treatment

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Treatment of atopic dermatitis'. Together they form a unique fingerprint.

Cite this